|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | ***Aarau*** | | ***Bern*** | | ***Bochum*** | | ***Athen*** | |
|  | *Relapse* | *Stable* | *Relapse* | *Stable* | *Relapse* | *Stable* | *Relapse* | *Stable* |
| ***Naïve*** | *10* | *47* | *29* | *64* | *18* | *31* | *9* | *22* |
| ***DMF*** | *3* | *12* | *26* | *49* | *18* | *31* | *5* | *20* |
| ***FTY*** | *7* | *35* | *3* | *15* | *0* | *0* | *4* | *2* |
| ***Injectables*** | *5* | *59* | *22* | *107* | *11* | *36* | *35* | *66* |
| ***DMF*** | *1* | *11* | *17* | *71* | *11* | *36* | *1* | *10* |
| ***FTY*** | *4* | *48* | *5* | *36* | *0* | *0* | *34* | *56* |
| ***Natalizumab*** | *10* | *53* | *15* | *31* | *3* | *6* | *0* | *4* |
| ***DMF*** | *3* | *12* | *15* | *19* | *3* | *6* | *0* | *2* |
| ***FTY*** | *7* | *41* | *0* | *12* | *0* | *0* | *0* | *2* |
| ***Other Oral*** | *1* | *7* | *5* | *11* | *5* | *6* | *2* | *2* |
| ***DMF*** | *1* | *5* | *2* | *5* | *5* | *6* | *2* | *1* |
| ***FTY*** | *0* | *2* | *3* | *6* | *0* | *0* | *0* | *1* |

Supplementary Table 1: Inclusion of patients per center stratified by treatment and outcome. Abbreviations: DMF: Dimethyl Fumarate; FTY: Fingolimod.